NCT07667478 · RECRUITING
NON-INVASIVE BRAIN STIMULATION FOR MEMORY LOSS IN EARLY ALZHEIMER'S DISEASE
This trial is testing whether repetitive transcranial magnetic stimulation (rTMS) — a non-invasive device that stimulates the brain from outside the skull — can improve short-term memory in people with early Alzheimer's disease or MCI due to Alzheimer's. Half the participants get real rTMS, half get a sham version. Memory tests and MRI scans track results before and after. This is a Phase NA (feasibility or pilot-level) study — it is exploratory, not a proven treatment.
Eligibility criteria
Inclusion Criteria: Participants must meet all of the following inclusion criteria to be eligible for enrollment: * A clinical diagnosis of early AD, defined as either mild cognitive impairment (MCI) due to AD or mild dementia due to AD; * Evidence of cognitive impairment, characterized by a MMSE score between 20 and 28 and/or a CDR-Sum of Boxes score between 0.5 and 8, consistent with the contemporary definitions used in early AD in clinical trials; and * Biomarker confirmation of AD pathology, demonstrated by a positive plasma phosphorylated tau-217 (p-tau217) result according to the 2024 National Institute on Aging-Alzheimer's Association (NIA-AA) diagnostic guidelines. Exclusion Criteria: * Exclusion criteria include evidence of other neurological, psychiatric, or systemic conditions that could cause cognitive and functional impairments (e.g., substantial concomitant cerebrovascular disease, alcoholism, certain medications that could have a substantial effect on cognition, untreated major depressive disorder, and heart, renal or hepatic failure). * Individuals who have contraindications to receiving rTMS, including a history of seizures or any non-removable metal in their heads or within 12 inches of the TMS coil will be excluded.
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-06-25